metformin (Glucophage), adiponectin, FTO inhibitors, and anti-inflammatory interventions represent promising approaches to disrupt the biochemical pathways that link obesity and cancer. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.